US Trials

Last updated: Tue Jun 04 18:36:37 PDT 2013
  1. Currently-recruiting dendritic vaccine trials (54)
  2. Enrolling-by-invitation dendritic vaccine trials (0)
  3. Active-but-not-recruiting dendritic vaccine trials (58)
  4. Completed dendritic vaccine trials (64)
  5. Not-yet-recruiting dendritic vaccine trials (4)

Currently-recruiting dendritic vaccine trials (54)

# Study
1

Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer

Status Currently-recruiting
Phase Unspecified
Conditions
Start date April 2013 End date March 2016
Study type INTERVENTIONAL
Interventions
NCT number NCT01823978

Go to top of page

2

Safety of Labeled Dendritic Cell (DC) Vaccines and Feasibility of Tracking by Magnetic Resonance Imaging (MRI)

Status Currently-recruiting
Phase Unspecified
Conditions
Start date January 2013 End date January 2014
Study type INTERVENTIONAL
Interventions
NCT number NCT01671592

Go to top of page

3

Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer

Status Currently-recruiting
Phase Unspecified
Conditions
Start date December 2012 End date Unspecified
Study type INTERVENTIONAL
Interventions
NCT number NCT01826877

Go to top of page

4

Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing

Status Currently-recruiting
Phase Unspecified
Conditions
Start date November 2012 End date June 2015
Study type INTERVENTIONAL
Interventions
NCT number NCT01730118

Go to top of page

5

Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies

Status Currently-recruiting
Phase Unspecified
Conditions
Start date November 2012 End date Unspecified
Study type INTERVENTIONAL
Interventions
NCT number NCT01697527

Go to top of page

6

Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells

Status Currently-recruiting
Phase Unspecified
Conditions
Start date October 2012 End date October 2014
Study type INTERVENTIONAL
Interventions
NCT number NCT01783431

Go to top of page

7

A Study of Vaccination With Poly-ICLC and Dendritic Cells in HLA-A2 Negative Patients With Pancreatic Adenocarcinoma

Status Currently-recruiting
Phase Unspecified
Conditions
Start date August 2012 End date August 2014
Study type INTERVENTIONAL
Interventions
NCT number NCT01677962

Go to top of page

8

Dendritic Cell Vaccine With or Without Gemcitabine Pre-Treatment for Adults and Children With Sarcoma

Status Currently-recruiting
Phase Unspecified
Conditions
Start date July 2012 End date July 2015
Study type INTERVENTIONAL
Interventions
NCT number NCT01803152

Go to top of page

9

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

Status Currently-recruiting
Phase Unspecified
Conditions Stage IIIA Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IV Ovarian Germ Cell Tumor, Stage I Rectal Cancer, Stage IIIC Rectal Cancer, Stage IIIB Melanoma, Recurrent Melanoma, Stage III Uterine Sarcoma, Adult Mixed Glioma, Chondrosarcoma, Recurrent Esophageal Cancer, Recurrent Prostate Cancer, Stage IIIB Ovarian Epithelial Cancer, Ovarian Sarcoma, Stage IIIA Gastric Cancer, Stage IVB Colon Cancer, Conjunctival Kaposi Sarcoma, Adult Gliosarcoma, Stage IIB Ovarian Germ Cell Tumor, Recurrent Small Cell Lung Cancer, Recurrent Osteosarcoma, Adult Anaplastic Astrocytoma, Stage IC Ovarian Germ Cell Tumor, Stage IIIB Esophageal Cancer, Stage IIB Colon Cancer, Stage IIIB Ovarian Germ Cell Tumor, Stage II Uterine Sarcoma, Male Breast Cancer, Stage IIB Gastric Cancer, Recurrent Adult Brain Tumor, Stage IIIA Breast Cancer, Recurrent Renal Cell Cancer, Stage IC Ovarian Epithelial Cancer, Stage IA Ovarian Epithelial Cancer, Stage IIIB Rectal Cancer, Stage IIIC Esophageal Cancer, Stage IIIA Ovarian Germ Cell Tumor, Stage IV Prostate Cancer, Stage IIA Colon Cancer, Stage IA Gastric Cancer, Recurrent Kaposi Sarcoma, Localized Resectable Adult Primary Liver Cancer, Stage IB Breast Cancer, Stage IB Ovarian Epithelial Cancer, Adult Anaplastic Oligodendroglioma, Stage IV Esophageal Cancer, Recurrent Colon Cancer, Stage IIB Ovarian Epithelial Cancer, Stage IIB Esophageal Cancer, Recurrent Ovarian Epithelial Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IV Uterine Sarcoma, Stage IV Gastric Cancer, Stage I Colon Cancer, Stage IIB Non-small Cell Lung Cancer, Adult Glioblastoma, Stage IIA Rectal Cancer, Recurrent Adult Primary Liver Cancer, Stage II Breast Cancer, Stage IIIA Rectal Cancer, Hormone-resistant Prostate Cancer, Stage IIB Melanoma, Recurrent Ovarian Germ Cell Tumor, Stage IIA Gastric Cancer, Small Intestine Leiomyosarcoma, Stage IVA Rectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific, Stage IIC Ovarian Epithelial Cancer, Stage IIIC Colon Cancer, Stage IIC Rectal Cancer, Stage IA Ovarian Germ Cell Tumor, Recurrent Bladder Cancer, Stage IV Ovarian Epithelial Cancer, Recurrent Rectal Cancer, Estrogen Receptor-positive Breast Cancer, Stage IIC Melanoma, Stage IIA Ovarian Germ Cell Tumor, Stage IB Ovarian Germ Cell Tumor, Stage IIIB Colon Cancer, Stage IV Melanoma, Stage IIIC Ovarian Germ Cell Tumor, Stage IIIA Melanoma, Stage IIIC Melanoma, Recurrent Adult Soft Tissue Sarcoma, Stage IIIB Gastric Cancer, Stage I Uterine Sarcoma, Adult Giant Cell Glioblastoma, Clear Cell Sarcoma of the Kidney, Mast Cell Sarcoma, Stage IIIC Breast Cancer, Stage IVA Colon Cancer, Recurrent Breast Cancer, Stage IV Bladder Cancer, Recurrent Gastric Cancer, Stage IB Gastric Cancer, Stage IIIC Gastric Cancer, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Adult Primary Hepatocellular Carcinoma, Stage IIA Ovarian Epithelial Cancer, Stage IA Breast Cancer, Recurrent Non-small Cell Lung Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IVB Rectal Cancer, Stage IIB Rectal Cancer, Stage IV Renal Cell Cancer, Estrogen Receptor-negative Breast Cancer, Stage IIC Colon Cancer, Stage IIC Ovarian Germ Cell Tumor, Stage IIIA Colon Cancer, Recurrent Uterine Sarcoma, Limited Stage Small Cell Lung Cancer, Stage IIIA Esophageal Cancer, Stage IIIB Breast Cancer
Start date March 2012 End date Unspecified
Study type INTERVENTIONAL
Interventions laboratory biomarker analysis, sirolimus, DEC-205-NY-ESO-1 fusion protein vaccine
NCT number NCT01522820

Go to top of page

10

Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma

Status Currently-recruiting
Phase Unspecified
Conditions
Start date January 2012 End date Unspecified
Study type INTERVENTIONAL
Interventions
NCT number NCT01635283

Go to top of page

11

Pilot Immunotherapy Trial for Recurrent Malignant Gliomas

Status Currently-recruiting
Phase Unspecified
Conditions Malignant Glioma of Brain
Start date January 2012 End date March 2014
Study type INTERVENTIONAL
Interventions IGF-1R/AS ODN, biodiffusion chamber
NCT number NCT01550523

Go to top of page

12

PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine

Status Currently-recruiting
Phase Unspecified
Conditions
Start date November 2011 End date Unspecified
Study type INTERVENTIONAL
Interventions
NCT number NCT01441765

Go to top of page

13

Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)

Status Currently-recruiting
Phase Unspecified
Conditions Prostate Cancer
Start date November 2011 End date Unspecified
Study type INTERVENTIONAL
Interventions sipuleucel-T
NCT number NCT01338012

Go to top of page

14

Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma

Status Currently-recruiting
Phase Unspecified
Conditions
Start date October 2011 End date October 2013
Study type INTERVENTIONAL
Interventions
NCT number NCT01456104

Go to top of page

15

A Vaccine Trial for Patients With Stage IIIB, IV, or Recurrent Non-Small Cell Lung Cancer

Status Currently-recruiting
Phase Unspecified
Conditions Non-Small Cell Lung Cancer (NSCLC)
Start date October 2011 End date September 2015
Study type INTERVENTIONAL
Interventions autologous dendritic cell adenovirus CCL21 vaccine
NCT number NCT01574222

Go to top of page

16

Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation

Status Currently-recruiting
Phase Unspecified
Conditions
Start date September 2011 End date March 2016
Study type INTERVENTIONAL
Interventions
NCT number NCT01483274

Go to top of page

17

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

Status Currently-recruiting
Phase Unspecified
Conditions Urothelial Carcinoma
Start date June 2011 End date Unspecified
Study type INTERVENTIONAL
Interventions DN24-02, Standard of Care
NCT number NCT01353222

Go to top of page

18

Study to Assess the Safety and Immunological Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI

Status Currently-recruiting
Phase Unspecified
Conditions Melanoma
Start date June 2011 End date May 2014
Study type INTERVENTIONAL
Interventions recMAGE-A3 + AS15 ASCI
NCT number NCT01425749

Go to top of page

19

Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals

Status Currently-recruiting
Phase Unspecified
Conditions HIV Infections
Start date May 2011 End date Unspecified
Study type INTERVENTIONAL
Interventions VRC-HIVDNA-016-00-VP, VRCHIVADV014-00-VP
NCT number NCT00955006

Go to top of page

20

Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer

Status Currently-recruiting
Phase Unspecified
Conditions Fallopian Tube Cancer, Primary Peritoneal Cancer, Ovarian Carcinoma
Start date March 2011 End date March 2016
Study type INTERVENTIONAL
Interventions cyclophosphamide 300 mg/m2/d for 3 days, fludarabine 30 mg/m2/d for 3 days, Bevacizumab, ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cells, OC-DC vaccine
NCT number NCT01312376

Go to top of page

21

IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma

Status Currently-recruiting
Phase Unspecified
Conditions
Start date January 2011 End date September 2014
Study type INTERVENTIONAL
Interventions
NCT number NCT01189383

Go to top of page

22

Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma

Status Currently-recruiting
Phase Unspecified
Conditions
Start date November 2010 End date Unspecified
Study type INTERVENTIONAL
Interventions
NCT number NCT01239875

Go to top of page

23

Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro

Status Currently-recruiting
Phase Unspecified
Conditions Multiple Myeloma
Start date October 2010 End date Unspecified
Study type OBSERVATIONAL
Interventions Blood draws
NCT number NCT01472627

Go to top of page

24

Dendritic Cell Vaccine for Patients With Brain Tumors

Status Currently-recruiting
Phase Unspecified
Conditions
Start date September 2010 End date Unspecified
Study type INTERVENTIONAL
Interventions
NCT number NCT01204684

Go to top of page

25

Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma

Status Currently-recruiting
Phase Unspecified
Conditions Rhabdomyosarcoma, Synovial Sarcoma, Ewings Sarcoma, Neuroblastoma, Osteogenic Sarcoma
Start date August 2010 End date August 2013
Study type INTERVENTIONAL
Interventions Autologous dendritic cell vaccine with adjuvant
NCT number NCT01241162

Go to top of page

26

Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission

Status Currently-recruiting
Phase Unspecified
Conditions
Start date May 2010 End date Unspecified
Study type INTERVENTIONAL
Interventions
NCT number NCT01096602

Go to top of page

27

Autologous OC-DC Vaccine in Ovarian Cancer

Status Currently-recruiting
Phase Unspecified
Conditions Chemotherapy, Ovarian Cancer, Tumor
Start date May 2010 End date May 2015
Study type INTERVENTIONAL
Interventions OCDC
NCT number NCT01132014

Go to top of page

28

Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor (PNET)

Status Currently-recruiting
Phase Unspecified
Conditions Medulloblastoma, Neuroectodermal Tumors
Start date April 2010 End date March 2015
Study type INTERVENTIONAL
Interventions TTRNA-xALT with TTRNA-DCs
NCT number NCT01326104

Go to top of page

29

Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation

Status Currently-recruiting
Phase Unspecified
Conditions
Start date March 2010 End date Unspecified
Study type INTERVENTIONAL
Interventions
NCT number NCT01067287

Go to top of page

30

Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12

Status Currently-recruiting
Phase Unspecified
Conditions
Start date December 2009 End date Unspecified
Study type INTERVENTIONAL
Interventions
NCT number NCT00622401

Go to top of page

31

Vaccine Therapy in Treating Patients With Metastatic Breast Cancer

Status Currently-recruiting
Phase Unspecified
Conditions
Start date December 2009 End date Unspecified
Study type INTERVENTIONAL
Interventions
NCT number NCT01042535

Go to top of page

32

Dendritic Cell Vaccine With Imiquimod for Patients With Malignant Glioma

Status Currently-recruiting
Phase Unspecified
Conditions
Start date October 2009 End date October 2014
Study type INTERVENTIONAL
Interventions
NCT number NCT01792505

Go to top of page

33

Study of Gene Modified Immune Cells in Patients With Advanced Melanoma

Status Currently-recruiting
Phase Unspecified
Conditions Metastatic Melanoma
Start date October 2009 End date Unspecified
Study type INTERVENTIONAL
Interventions F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells, non-myeloablative conditioning chemotherapy
NCT number NCT00910650

Go to top of page

34

Vaccine Therapy in Treating Patients Undergoing Surgery for Recurrent Glioblastoma Multiforme

Status Currently-recruiting
Phase Unspecified
Conditions
Start date September 2009 End date September 2015
Study type INTERVENTIONAL
Interventions
NCT number NCT00890032

Go to top of page

35

Host Dendritic Cells in Allograft Patients

Status Currently-recruiting
Phase Unspecified
Conditions Multiple Myeloma, Chronic Lymphocytic Lymphoma, Relapsed Non-Hodgkin’s Lymphoma, Hodgkin’s Disease
Start date August 2009 End date Unspecified
Study type INTERVENTIONAL
Interventions MSSM/BIIR HDC Vax-001 (Host Dendritic Cells)
NCT number NCT00935597

Go to top of page

36

Vaccine Therapy in Treating Patients With Ductal Carcinoma In Situ of the Breast

Status Currently-recruiting
Phase Unspecified
Conditions Breast Cancer
Start date March 2009 End date Unspecified
Study type INTERVENTIONAL
Interventions therapeutic autologous dendritic cells, HER-2/neu peptide vaccine
NCT number NCT00923143

Go to top of page

37

Anti-TNF Agents for the Treatment of Rheumatoid Arthritis

Status Currently-recruiting
Phase Unspecified
Conditions Rheumatoid Arthritis
Start date March 2009 End date September 2013
Study type INTERVENTIONAL
Interventions Etanercept, Adalimumab
NCT number NCT00837434

Go to top of page

38

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Status Currently-recruiting
Phase Unspecified
Conditions Lung Cancer
Start date February 2009 End date Unspecified
Study type INTERVENTIONAL
Interventions autologous dendritic cell-adenovirus CCL21 vaccine
NCT number NCT00601094

Go to top of page

39

Ovarian Dendritic Cell Vaccine Trial

Status Currently-recruiting
Phase Unspecified
Conditions
Start date October 2008 End date July 2013
Study type INTERVENTIONAL
Interventions
NCT number NCT00703105

Go to top of page

40

Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma

Status Currently-recruiting
Phase Unspecified
Conditions
Start date August 2008 End date September 2013
Study type INTERVENTIONAL
Interventions
NCT number NCT00683670

Go to top of page

41

A Phase I Cancer Vaccine Study for Patients With Metastatic Breast Cancer

Status Currently-recruiting
Phase Unspecified
Conditions
Start date May 2008 End date February 2015
Study type INTERVENTIONAL
Interventions
NCT number NCT00715832

Go to top of page

42

Human Immune Responses to The Yellow Fever Virus Vaccine

Status Currently-recruiting
Phase Unspecified
Conditions Yellow Fever
Start date May 2008 End date December 2015
Study type INTERVENTIONAL
Interventions
NCT number NCT00694655

Go to top of page

43

Wilm’s Tumor 1 Protein Vaccine to Treat Cancers of the Blood

Status Currently-recruiting
Phase Unspecified
Conditions
Start date January 2008 End date November 2015
Study type INTERVENTIONAL
Interventions
NCT number NCT00923910

Go to top of page

44

A Study of HIV-infected Subjects Initiating Anti-HIV Drugs for the First Time

Status Currently-recruiting
Phase Unspecified
Conditions HIV Infections
Start date January 2008 End date Unspecified
Study type OBSERVATIONAL
Interventions
NCT number NCT00595192

Go to top of page

45

To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid

Status Currently-recruiting
Phase Unspecified
Conditions Small Cell Lung Cancer
Start date October 2007 End date June 2014
Study type INTERVENTIONAL
Interventions Drug: Ad.p53-DC vaccines, Paclitaxel
NCT number NCT00617409

Go to top of page

46

Vaccine Therapy and Chemotherapy With or Without Tretinoin in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Status Currently-recruiting
Phase Unspecified
Conditions Lung Cancer
Start date July 2007 End date Unspecified
Study type INTERVENTIONAL
Interventions tretinoin, standard follow-up care, autologous dendritic cell-adenovirus p53 vaccine
NCT number NCT00618891

Go to top of page

47

Autologous Dendritic Cells Pulsed With Autologous Apoptotic Tumor Cells Administered to Patients With Brain Tumors

Status Currently-recruiting
Phase Unspecified
Conditions Brain Tumors
Start date June 2007 End date December 2012
Study type INTERVENTIONAL
Interventions DC/AAT-Flu, DC/KLH, DC/AAT
NCT number NCT00893945

Go to top of page

48

Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma

Status Currently-recruiting
Phase Unspecified
Conditions Melanoma (Skin)
Start date December 2006 End date Unspecified
Study type INTERVENTIONAL
Interventions therapeutic autologous dendritic cells, autologous tumor cell vaccine, sargramostim
NCT number NCT00436930

Go to top of page

49

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

Status Currently-recruiting
Phase Unspecified
Conditions GBM, Glioblastoma Multiforme, Grade IV Astrocytoma, Glioblastoma, Brain Cancer, Glioma, Brain Tumor
Start date December 2006 End date Unspecified
Study type INTERVENTIONAL
Interventions Dendritic Cell Immunotherapy
NCT number NCT00045968

Go to top of page

50

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization

Status Currently-recruiting
Phase Unspecified
Conditions Melanoma
Start date February 2006 End date Unspecified
Study type INTERVENTIONAL
Interventions Interleukin-2, Fludarabine, Dendritic Cell Immunization, Mesna, T Cells, cyclophosphamide
NCT number NCT00338377

Go to top of page

51

Vaccine Therapy in Treating Patients With Newly Diagnosed Stage IV Kidney Cancer

Status Currently-recruiting
Phase Unspecified
Conditions Kidney Cancer
Start date September 2005 End date Unspecified
Study type INTERVENTIONAL
Interventions autologous dendritic cell-autologous tumor mRNA-human CD40L vaccine, therapeutic autologous dendritic cells
NCT number NCT00309829

Go to top of page

52

Vaccine Therapy in Treating Patients With Head and Neck Cancer

Status Currently-recruiting
Phase Unspecified
Conditions Head and Neck Cancer
Start date September 2005 End date Unspecified
Study type INTERVENTIONAL
Interventions tetanus toxoid helper peptide, mutant p53 peptide pulsed dendritic cell vaccine, adjuvant therapy
NCT number NCT00404339

Go to top of page

53

Immunization Against Tumor Cells in Sezary Syndrome

Status Currently-recruiting
Phase Unspecified
Conditions Sezary Syndrome, Cutaneous T-Cell Lymphoma
Start date September 2004 End date December 2008
Study type INTERVENTIONAL
Interventions autologous dendritic cell vaccine
NCT number NCT00099593

Go to top of page

54

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Status Currently-recruiting
Phase Unspecified
Conditions
Start date March 2004 End date Unspecified
Study type INTERVENTIONAL
Interventions
NCT number NCT00085397

Go to top of page

Active-but-not-recruiting dendritic vaccine trials (58)

# Study
1

The Effects of GLA (5 Mcg) on Human Volunteers

Status Active-but-not-recruiting
Phase Unspecified
Conditions
Start date September 2012 End date September 2013
Study type INTERVENTIONAL
Interventions
NCT number NCT01864876

Go to top of page

2

Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults

Status Active-but-not-recruiting
Phase Unspecified
Conditions
Start date April 2012 End date Unspecified
Study type INTERVENTIONAL
Interventions
NCT number NCT01571960

Go to top of page

3

Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study

Status Active-but-not-recruiting
Phase Unspecified
Conditions Epithelial Ovarian Cancer
Start date December 2011 End date December 2013
Study type INTERVENTIONAL
Interventions MUC1 Dendritic Cell Vaccine (Cvac)
NCT number NCT01617629

Go to top of page

4

Concurrent Versus Sequential Treatment With Sipuleucel-T and Abiraterone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Status Active-but-not-recruiting
Phase Unspecified
Conditions Prostate Cancer Metastatic, Hormone Refractory Prostate Cancer
Start date December 2011 End date Unspecified
Study type INTERVENTIONAL
Interventions sipuleucel-T, abiraterone acetate
NCT number NCT01487863

Go to top of page

5

Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer

Status Active-but-not-recruiting
Phase Unspecified
Conditions Prostatic Neoplasm, Prostate Cancer, Prostatic Adenocarcinoma
Start date September 2011 End date August 2014
Study type INTERVENTIONAL
Interventions sipuleucel-T, leuprolide acetate
NCT number NCT01431391

Go to top of page

6

The Effects of GLA on Human Volunteers

Status Active-but-not-recruiting
Phase Unspecified
Conditions Healthy Volunteers
Start date July 2011 End date January 2013
Study type INTERVENTIONAL
Interventions GLA-SE, GLA-AF, Squalene
NCT number NCT01397604

Go to top of page

7

A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)

Status Active-but-not-recruiting
Phase Unspecified
Conditions Glioblastoma Multiforme
Start date January 2011 End date Unspecified
Study type INTERVENTIONAL
Interventions ICT-107, Placebo DC
NCT number NCT01280552

Go to top of page

8

Ovarian Cancer Vaccine for Patients in Remission

Status Active-but-not-recruiting
Phase Unspecified
Conditions Epithelial Ovarian Cancer
Start date June 2010 End date October 2013
Study type INTERVENTIONAL
Interventions MUC1 Dendritic Cell Vaccine (Cvac)
NCT number NCT01068509

Go to top of page

9

DCVax Plus Poly ICLC in Healthy Volunteers

Status Active-but-not-recruiting
Phase Unspecified
Conditions HIV-1 Infection, HIV Infection, Healthy Volunteers
Start date May 2010 End date May 2013
Study type INTERVENTIONAL
Interventions Placebo, Poly-ICLC, DCVax-001
NCT number NCT01127464

Go to top of page

10

Study to Evaluate the Safety and Immunogenicity of Poly ICLC (Hiltonol) in Healthy Volunteers

Status Active-but-not-recruiting
Phase Unspecified
Conditions Healthy Volunteers
Start date November 2009 End date February 2013
Study type INTERVENTIONAL
Interventions Hiltonol (poly ICLC)
NCT number NCT01012700

Go to top of page

11

Alpha-Type 1 Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer

Status Active-but-not-recruiting
Phase Unspecified
Conditions
Start date September 2009 End date September 2013
Study type INTERVENTIONAL
Interventions
NCT number NCT00970203

Go to top of page

12

A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects

Status Active-but-not-recruiting
Phase Unspecified
Conditions
Start date August 2009 End date December 2014
Study type INTERVENTIONAL
Interventions
NCT number NCT00833781

Go to top of page

13

Open Label Study of Sipuleucel-T

Status Active-but-not-recruiting
Phase Unspecified
Conditions Prostate Cancer
Start date August 2009 End date December 2013
Study type INTERVENTIONAL
Interventions sipuleucel-T
NCT number NCT00901342

Go to top of page

14

A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer

Status Active-but-not-recruiting
Phase Unspecified
Conditions Prostatic Neoplasms, Prostate Specific Antigens
Start date April 2009 End date Unspecified
Study type INTERVENTIONAL
Interventions TARP 29-37-9V Peptide Epitope Enchanced Peptide, TARP 29-35 Peptide (Native Peptide)
NCT number NCT00972309

Go to top of page

15

Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients

Status Active-but-not-recruiting
Phase Unspecified
Conditions Metastatic Renal Cell Carcinoma
Start date February 2009 End date January 2016
Study type INTERVENTIONAL
Interventions IL-2, IFN, Bevacizumab, DC vaccine
NCT number NCT00913913

Go to top of page

16

Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod

Status Active-but-not-recruiting
Phase Unspecified
Conditions
Start date August 2008 End date June 2013
Study type INTERVENTIONAL
Interventions
NCT number NCT00799110

Go to top of page

17

Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer

Status Active-but-not-recruiting
Phase Unspecified
Conditions Breast Cancer
Start date August 2008 End date Unspecified
Study type INTERVENTIONAL
Interventions immunologic technique, incomplete Freund’s adjuvant, sargramostim, MUC-1 peptide vaccine, HER-2/neu peptide vaccine, CpG oligodeoxynucleotide, immunoenzyme technique
NCT number NCT00640861

Go to top of page

18

To Evaluate Sipuleucel-T Manufactured With Different Concentrations of PA2024 Antigen

Status Active-but-not-recruiting
Phase Unspecified
Conditions Prostate Cancer
Start date August 2008 End date Unspecified
Study type INTERVENTIONAL
Interventions sipuleucel-T
NCT number NCT00715078

Go to top of page

19

Phase I Trial of TGFB2-Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine for Advanced Cancer

Status Active-but-not-recruiting
Phase Unspecified
Conditions
Start date May 2008 End date Unspecified
Study type INTERVENTIONAL
Interventions TGFβ2 Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine
NCT number NCT00684294

Go to top of page

20

Cellular Immunotherapy Study With Autologous Dendritic Cells Loaded With Oncofetal Antigen/iLRP in Patients With Metastatic Breast Cancer

Status Active-but-not-recruiting
Phase Unspecified
Conditions Breast Cancer
Start date May 2008 End date September 2011
Study type INTERVENTIONAL
Interventions Dendritic cell vaccination
NCT number NCT00879489

Go to top of page

21

Alpha-type-1 Dendritic Cell-based Vaccines in Patients With Metastatic Colorectal Cancer

Status Active-but-not-recruiting
Phase Unspecified
Conditions
Start date January 2008 End date July 2014
Study type INTERVENTIONAL
Interventions
NCT number NCT00558051

Go to top of page

22

Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells

Status Active-but-not-recruiting
Phase Unspecified
Conditions Metastatic Melanoma, Absence of CNS Metastases
Start date January 2008 End date March 2013
Study type INTERVENTIONAL
Interventions Proteasome siRNA and tumor antigen RNA-transfected dendritic cells
NCT number NCT00672542

Go to top of page

23

Autologous Dendritic Cell Vaccine in HIV1 Infection

Status Active-but-not-recruiting
Phase Unspecified
Conditions
Start date July 2007 End date September 2012
Study type INTERVENTIONAL
Interventions
NCT number NCT00510497

Go to top of page

24

A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML)

Status Active-but-not-recruiting
Phase Unspecified
Conditions Acute Myelogenous Leukemia
Start date July 2007 End date February 2015
Study type INTERVENTIONAL
Interventions GRNVAC1
NCT number NCT00510133

Go to top of page

25

Autologous Dendritic Cell Therapy for Type 1 Diabetes Suppression: A Safety Study

Status Active-but-not-recruiting
Phase Unspecified
Conditions
Start date March 2007 End date June 2011
Study type INTERVENTIONAL
Interventions
NCT number NCT00445913

Go to top of page

26

Daclizumab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia

Status Active-but-not-recruiting
Phase Unspecified
Conditions
Start date March 2007 End date March 2014
Study type INTERVENTIONAL
Interventions RNA-loaded dendritic cell vaccine, cytomegalovirus pp65-specific cytotoxic T lymphocytes
NCT number NCT00626483

Go to top of page

27

Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas

Status Active-but-not-recruiting
Phase Unspecified
Conditions
Start date December 2006 End date December 2013
Study type INTERVENTIONAL
Interventions
NCT number NCT00766753

Go to top of page

28

Direct Tumor Injection KLH-Pulsed Dendritic Cells in Unresectable Pancreatic Cancer

Status Active-but-not-recruiting
Phase Unspecified
Conditions
Start date July 2006 End date Unspecified
Study type INTERVENTIONAL
Interventions
NCT number NCT00868114

Go to top of page

29

Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer

Status Active-but-not-recruiting
Phase Unspecified
Conditions
Start date June 2006 End date December 2012
Study type INTERVENTIONAL
Interventions
NCT number NCT00345293

Go to top of page

30

A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation

Status Active-but-not-recruiting
Phase Unspecified
Conditions Sarcoma, Wilm’s Tumor, Neuroblastoma
Start date June 2006 End date December 2013
Study type INTERVENTIONAL
Interventions hematopoietic stem cell transplantation (HSCT), tumor lysate-pulsed dendritic cell vaccine
NCT number NCT00405327

Go to top of page

31

MUC1 Vaccine in Conjunction With Poly-ICLC in Patients With Recurrent and/or Advanced Prostate Cancer

Status Active-but-not-recruiting
Phase Unspecified
Conditions Prostate Cancer
Start date June 2006 End date July 2013
Study type INTERVENTIONAL
Interventions MUC_1
NCT number NCT00374049

Go to top of page

32

Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme

Status Active-but-not-recruiting
Phase Unspecified
Conditions
Start date May 2006 End date December 2013
Study type INTERVENTIONAL
Interventions
NCT number NCT00323115
Results Has Results

Go to top of page

33

Vaccine Therapy in Treating Patients With Malignant Glioma

Status Active-but-not-recruiting
Phase Unspecified
Conditions
Start date May 2006 End date Unspecified
Study type INTERVENTIONAL
Interventions
NCT number NCT00612001

Go to top of page

34

Combined Modality Treatment for Patients With Stage IV Melanoma

Status Active-but-not-recruiting
Phase Unspecified
Conditions
Start date March 2006 End date March 2012
Study type INTERVENTIONAL
Interventions
NCT number NCT00313235

Go to top of page

35

Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Status Active-but-not-recruiting
Phase Unspecified
Conditions
Start date January 2006 End date December 2016
Study type INTERVENTIONAL
Interventions tetanus toxoid, therapeutic autologous lymphocytes, therapeutic autologous dendritic cells
NCT number NCT00639639

Go to top of page

36

Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Status Active-but-not-recruiting
Phase Unspecified
Conditions Breast Cancer
Start date December 2005 End date May 2014
Study type INTERVENTIONAL
Interventions vinorelbine ditartrate, sargramostim, therapeutic autologous dendritic cells, trastuzumab
NCT number NCT00266110

Go to top of page

37

Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine

Status Active-but-not-recruiting
Phase Unspecified
Conditions Melanoma
Start date July 2005 End date December 2013
Study type INTERVENTIONAL
Interventions KLH, peptides plus Montanide, KLH; Peptides; Dendritic Cells
NCT number NCT00124124

Go to top of page

38

GVAX in Advanced Prostate Cancer Patients Made Lymphopenic

Status Active-but-not-recruiting
Phase Unspecified
Conditions Prostate Cancer
Start date July 2005 End date July 2005
Study type INTERVENTIONAL
Interventions GM-CSF gene transduced allogeneic vaccine GVAX
NCT number NCT00122005

Go to top of page

39

Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer

Status Active-but-not-recruiting
Phase Unspecified
Conditions Metastatic Cancer, Colorectal Cancer
Start date February 2005 End date Unspecified
Study type INTERVENTIONAL
Interventions inalimarev, sargramostim, falimarev, therapeutic autologous dendritic cells
NCT number NCT00103142

Go to top of page

40

Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV Melanoma

Status Active-but-not-recruiting
Phase Unspecified
Conditions Cutaneous Melanoma
Start date January 2005 End date Unspecified
Study type INTERVENTIONAL
Interventions autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine
NCT number NCT00107159

Go to top of page

41

Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Ductal Carcinoma In Situ of the Breast

Status Active-but-not-recruiting
Phase Unspecified
Conditions Breast Cancer
Start date January 2005 End date Unspecified
Study type INTERVENTIONAL
Interventions conventional surgery, therapeutic autologous dendritic cells, neoadjuvant therapy
NCT number NCT00107211

Go to top of page

42

Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF

Status Active-but-not-recruiting
Phase Unspecified
Conditions
Start date October 2004 End date December 2013
Study type INTERVENTIONAL
Interventions
NCT number NCT00458536

Go to top of page

43

Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer

Status Active-but-not-recruiting
Phase Unspecified
Conditions Lung Cancer
Start date October 2004 End date Unspecified
Study type INTERVENTIONAL
Interventions therapeutic autologous dendritic cells
NCT number NCT00103116

Go to top of page

44

Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer

Status Active-but-not-recruiting
Phase Unspecified
Conditions Kidney Cancer
Start date August 2004 End date Unspecified
Study type INTERVENTIONAL
Interventions keyhole limpet hemocyanin, autologous tumor cell vaccine, conventional surgery, fludarabine phosphate, therapeutic autologous dendritic cells
NCT number NCT00093522

Go to top of page

45

Vaccine Therapy With Either Neoadjuvant or Adjuvant Chemotherapy and Adjuvant Radiation Therapy in Treating Women With p53-Overexpressing Stage III Breast Cancer

Status Active-but-not-recruiting
Phase Unspecified
Conditions Breast Cancer
Start date January 2004 End date Unspecified
Study type INTERVENTIONAL
Interventions autologous dendritic cell-adenovirus p53 vaccine
NCT number NCT00082641

Go to top of page

46

Vaccine Therapy in Treating Patients With Malignant Glioma

Status Active-but-not-recruiting
Phase Unspecified
Conditions Brain and Central Nervous System Tumors
Start date June 2003 End date Unspecified
Study type INTERVENTIONAL
Interventions therapeutic autologous dendritic cells
NCT number NCT00068510

Go to top of page

47

Chemotherapy Followed By Vaccine Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Status Active-but-not-recruiting
Phase Unspecified
Conditions Lung Cancer
Start date April 2003 End date August 2013
Study type INTERVENTIONAL
Interventions etoposide, carboplatin, autologous dendritic cell-adenovirus p53 vaccine
NCT number NCT00049218

Go to top of page

48

Dendritic Cells (DC) Vaccine for Metastatic Melanoma

Status Active-but-not-recruiting
Phase Unspecified
Conditions
Start date October 2002 End date October 2015
Study type INTERVENTIONAL
Interventions
NCT number NCT01042366

Go to top of page

49

Vaccine Therapy in Treating Patients With Kidney Cancer

Status Active-but-not-recruiting
Phase Unspecified
Conditions Kidney Cancer
Start date November 2001 End date Unspecified
Study type INTERVENTIONAL
Interventions therapeutic autologous dendritic cells, autologous tumor cell vaccine
NCT number NCT00014131

Go to top of page

50

Provenge (TM) for the Treatment of Hormone Sensitive Prostate Cancer

Status Active-but-not-recruiting
Phase Unspecified
Conditions Prostate Cancer
Start date September 2001 End date Unspecified
Study type INTERVENTIONAL
Interventions Provenge, Placebo
NCT number NCT00779402

Go to top of page

51

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Status Active-but-not-recruiting
Phase Unspecified
Conditions Melanoma (Skin)
Start date April 2001 End date Unspecified
Study type INTERVENTIONAL
Interventions therapeutic autologous dendritic cells, filgrastim
NCT number NCT00017355

Go to top of page

52

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Status Active-but-not-recruiting
Phase Unspecified
Conditions Prostate Cancer
Start date December 2000 End date Unspecified
Study type INTERVENTIONAL
Interventions therapeutic autologous dendritic cells, PSA prostate cancer vaccine
NCT number NCT00005992

Go to top of page

53

The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma

Status Active-but-not-recruiting
Phase Unspecified
Conditions Metastatic Melanoma
Start date July 2000 End date November 2008
Study type INTERVENTIONAL
Interventions DC/tumor fusion vaccine
NCT number NCT00626860

Go to top of page

54

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

Status Active-but-not-recruiting
Phase Unspecified
Conditions Melanoma (Skin)
Start date March 1999 End date Unspecified
Study type INTERVENTIONAL
Interventions aldesleukin, dendritic cell-gp100-MART-1 antigen vaccine
NCT number NCT00004025

Go to top of page

55

Immunotherapy in Treating Patients With Metastatic Breast Cancer

Status Active-but-not-recruiting
Phase Unspecified
Conditions Breast Cancer
Start date June 1998 End date Unspecified
Study type INTERVENTIONAL
Interventions carcinoembryonic antigen RNA-pulsed DC cancer vaccine
NCT number NCT00003432

Go to top of page

56

Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

Status Active-but-not-recruiting
Phase Unspecified
Conditions Melanoma (Skin)
Start date April 1998 End date Unspecified
Study type INTERVENTIONAL
Interventions incomplete Freund’s adjuvant, gp100 antigen, aldesleukin, tetanus peptide melanoma vaccine, tyrosinase peptide, sargramostim
NCT number NCT00003222

Go to top of page

57

HIV Candidate Vaccine, ALVAC-HIV-1, Administration in HIV-Negative Adults

Status Active-but-not-recruiting
Phase Unspecified
Conditions HIV Seronegativity, HIV Infections
Start date End date Unspecified
Study type INTERVENTIONAL
Interventions ALVAC-HIV MN120TMG (vCP205)
NCT number NCT00013572

Go to top of page

58

Active Immunotherapy Of Metastatic Renal Cell Carcinoma Using Autologous Dendritic Cells Transfected With Autologous Total Tumor RNA

Status Active-but-not-recruiting
Phase Unspecified
Conditions Renal Cell Carcinoma
Start date End date Unspecified
Study type INTERVENTIONAL
Interventions DC RCC-RNA
NCT number NCT00006431

Go to top of page

Completed dendritic vaccine trials (64)

# Study
1

Polyinosinic-Polycytidylic Acid-poly-L-lysine Carboxymethylcellulose (Poly-ICLC) in Healthy Volunteers

Status Completed
Phase Unspecified
Conditions Healthy Volunteers
Start date June 2011 End date September 2011
Study type INTERVENTIONAL
Interventions Poly ICLC
NCT number NCT01299662

Go to top of page

2

Early Immune Responses to Vaccination – A Substudy to HVTN 205

Status Completed
Phase Unspecified
Conditions HIV Infections
Start date August 2009 End date July 2012
Study type OBSERVATIONAL
Interventions JS7 DNA vaccine, MVA/HIV62 vaccine
NCT number NCT00908323

Go to top of page

3

Vaccination of HIV-1 Infected Patients With Dendritic Cells in Addition to Antiretroviral Treatment – (DALIA Trial)

Status Completed
Phase Unspecified
Conditions
Start date November 2008 End date September 2011
Study type INTERVENTIONAL
Interventions
NCT number NCT00796770

Go to top of page

4

Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured

Status Completed
Phase Unspecified
Conditions Melanoma (Skin)
Start date November 2008 End date April 2012
Study type INTERVENTIONAL
Interventions autologous dendritic cell-adenovirus CCL21 vaccine
NCT number NCT00798629

Go to top of page

5

Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients

Status Completed
Phase Unspecified
Conditions
Start date June 2008 End date July 2012
Study type INTERVENTIONAL
Interventions
NCT number NCT00722098

Go to top of page

6

A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer

Status Completed
Phase Unspecified
Conditions Peritoneal Cancer, Ovarian Cancer
Start date November 2007 End date December 2009
Study type INTERVENTIONAL
Interventions DCVac-L
NCT number NCT00683241

Go to top of page

7

Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma

Status Completed
Phase Unspecified
Conditions Brain Stem Glioma, Glioblastoma
Start date May 2007 End date April 2012
Study type INTERVENTIONAL
Interventions dendritic cell vaccine
NCT number NCT00576641

Go to top of page

8

Surgical Resection With Gliadel Wafer Followed by Dendritic Cells Vaccination for Malignant Glioma Patients

Status Completed
Phase Unspecified
Conditions
Start date April 2007 End date May 2012
Study type INTERVENTIONAL
Interventions
NCT number NCT00576446

Go to top of page

9

Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung Cancer

Status Completed
Phase Unspecified
Conditions
Start date October 2006 End date June 2012
Study type INTERVENTIONAL
Interventions
NCT number NCT00601796
Results Has Results

Go to top of page

10

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Status Completed
Phase Unspecified
Conditions
Start date October 2006 End date Unspecified
Study type INTERVENTIONAL
Interventions
NCT number NCT00390338

Go to top of page

11

External Beam Radiation With Intratumoral Injection Of Dendritic Cells As Neo-Adjuvant Treatment for Sarcoma

Status Completed
Phase Unspecified
Conditions Soft Tissue Sarcoma
Start date June 2006 End date June 2012
Study type INTERVENTIONAL
Interventions Surgery for tumor removal, Radiation therapy, Dendritic cell injections
NCT number NCT00365872

Go to top of page

12

Yellow Fever Virus Vaccine and Immune Globulin Study

Status Completed
Phase Unspecified
Conditions Viremia, Immune Response to Yellow Fever Virus Vaccination
Start date June 2006 End date November 2008
Study type INTERVENTIONAL
Interventions YF-VAX and Gama STAN S/D
NCT number NCT00254826

Go to top of page

13

Dendritic Cell Vaccination During Lymphoid Reconstruction

Status Completed
Phase Unspecified
Conditions Intraocular Melanoma, Melanoma (Skin)
Start date February 2006 End date March 2012
Study type INTERVENTIONAL
Interventions
NCT number NCT00313508

Go to top of page

14

Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer

Status Completed
Phase Unspecified
Conditions Breast Cancer, Pancreatic Cancer, Colorectal Cancer, Ovarian Cancer, Bladder Cancer
Start date January 2006 End date December 2009
Study type INTERVENTIONAL
Interventions CDX-1307
NCT number NCT00648102

Go to top of page

15

Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer

Status Completed
Phase Unspecified
Conditions Pancreatic Cancer, Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific, Breast Cancer, Colorectal Cancer
Start date September 2005 End date May 2009
Study type INTERVENTIONAL
Interventions denileukin diftitox, therapeutic autologous dendritic cells, recombinant fowlpox-CEA(6D)/TRICOM vaccine
NCT number NCT00128622

Go to top of page

16

Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients

Status Completed
Phase Unspecified
Conditions Ovarian Cancer
Start date August 2005 End date August 2008
Study type INTERVENTIONAL
Interventions DC-Ova
NCT number NCT00478452

Go to top of page

17

NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)

Status Completed
Phase Unspecified
Conditions Malignant Melanoma
Start date August 2005 End date June 2007
Study type INTERVENTIONAL
Interventions imiquimod, NY-ESO-1 protein
NCT number NCT00142454

Go to top of page

18

Vaccination of Patients With Stage IV Melanoma With Dendritic Cells

Status Completed
Phase Unspecified
Conditions Melanoma, Neoplasm Metastasis
Start date July 2005 End date June 2007
Study type INTERVENTIONAL
Interventions Dendritic cell vaccination
NCT number NCT00125749

Go to top of page

19

Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma

Status Completed
Phase Unspecified
Conditions Multiple Myeloma
Start date April 2005 End date April 2012
Study type INTERVENTIONAL
Interventions Dendritic Cell Tumor Fusion
NCT number NCT00458653

Go to top of page

20

Vaccine Therapy in Treating Young Patients Who Are Undergoing Surgery for Malignant Glioma

Status Completed
Phase Unspecified
Conditions Brain and Central Nervous System Tumors
Start date January 2005 End date March 2010
Study type INTERVENTIONAL
Interventions therapeutic autologous dendritic cells
NCT number NCT00107185

Go to top of page

21

The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma

Status Completed
Phase Unspecified
Conditions
Start date July 2004 End date November 2009
Study type INTERVENTIONAL
Interventions
NCT number NCT00459069

Go to top of page

22

Evaluation of the Effects of Local Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes: MEL38

Status Completed
Phase Unspecified
Conditions Melanoma
Start date June 2004 End date Unspecified
Study type INTERVENTIONAL
Interventions GM-CSF-in-adjuvant, Saline, GM-CSF and Montanide ISA-51, Montanide ISA-51
NCT number NCT00912574

Go to top of page

23

CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery

Status Completed
Phase Unspecified
Conditions Melanoma (Skin)
Start date April 2004 End date October 2009
Study type INTERVENTIONAL
Interventions
NCT number NCT00090896

Go to top of page

24

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Status Completed
Phase Unspecified
Conditions Melanoma (Skin)
Start date February 2004 End date Unspecified
Study type INTERVENTIONAL
Interventions autologous tumor cell vaccine, therapeutic autologous dendritic cells
NCT number NCT00085488

Go to top of page

25

RNA-Loaded Dendritic Cell Cancer Vaccine

Status Completed
Phase Unspecified
Conditions Renal Cell Carcinoma
Start date January 2004 End date September 2008
Study type INTERVENTIONAL
Interventions MB-002
NCT number NCT00087984

Go to top of page

26

Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer

Status Completed
Phase Unspecified
Conditions Breast Cancer
Start date January 2004 End date Unspecified
Study type INTERVENTIONAL
Interventions trastuzumab, therapeutic autologous dendritic cells, vinorelbine ditartrate
NCT number NCT00088985

Go to top of page

27

DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC

Status Completed
Phase Unspecified
Conditions Kidney Cancer
Start date December 2003 End date October 2009
Study type INTERVENTIONAL
Interventions Aldesleukin,, recombinant interferon alfa, autologous tumor cell vaccine
NCT number NCT00085436

Go to top of page

28

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Status Completed
Phase Unspecified
Conditions Melanoma (Skin), Intraocular Melanoma
Start date October 2003 End date June 2005
Study type INTERVENTIONAL
Interventions therapeutic autologous dendritic cells, MART-1 antigen, gp100:209-217(210M) peptide vaccine, tyrosinase peptide
NCT number NCT00334776

Go to top of page

29

Vaccine Therapy in Treating Patients With Refractory Stage IV Cancer

Status Completed
Phase Unspecified
Conditions Unspecified Adult Solid Tumor, Protocol Specific
Start date September 2003 End date September 2006
Study type INTERVENTIONAL
Interventions
NCT number NCT00057915

Go to top of page

30

Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy

Status Completed
Phase Unspecified
Conditions Prostate Cancer
Start date July 2003 End date January 2009
Study type INTERVENTIONAL
Interventions sipuleucel-T, APC-Placebo
NCT number NCT00065442
Results Has Results

Go to top of page

31

Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells

Status Completed
Phase Unspecified
Conditions Multiple Myeloma
Start date April 2003 End date December 2008
Study type INTERVENTIONAL
Interventions Idiotype-pulsed allogeneic dendritic cells
NCT number NCT00186316

Go to top of page

32

HIV Vaccine Designed for HIV Infected Adults Taking Anti-HIV Drugs

Status Completed
Phase Unspecified
Conditions HIV Infections
Start date February 2003 End date Unspecified
Study type INTERVENTIONAL
Interventions Autologous Dendritic Cell HIV Vaccination
NCT number NCT00056758

Go to top of page

33

A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma

Status Completed
Phase Unspecified
Conditions Renal Cell Carcinoma
Start date December 2002 End date February 2008
Study type INTERVENTIONAL
Interventions Electrofusion DC vaccine
NCT number NCT00625755

Go to top of page

34

Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney Cancer

Status Completed
Phase Unspecified
Conditions Carcinoma, Renal Cell
Start date November 2002 End date Unspecified
Study type INTERVENTIONAL
Interventions Allogeneic DCs and Autologous RCC Tumor Derived Cells
NCT number NCT00050323

Go to top of page

35

Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients’ Own Immune Cells.

Status Completed
Phase Unspecified
Conditions
Start date March 2002 End date November 2008
Study type INTERVENTIONAL
Interventions
NCT number NCT00289341
Results Has Results

Go to top of page

36

Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma

Status Completed
Phase Unspecified
Conditions Melanoma (Skin)
Start date March 2002 End date June 2009
Study type INTERVENTIONAL
Interventions dendritic cell-MART-1 peptide vaccine
NCT number NCT00039325

Go to top of page

37

Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer

Status Completed
Phase Unspecified
Conditions Gallbladder Cancer, Pancreatic Cancer, Head and Neck Cancer, Ovarian Cancer, Colorectal Cancer, Testicular Germ Cell Tumor, Breast Cancer, Liver Cancer, Gastric Cancer
Start date January 2002 End date October 2007
Study type INTERVENTIONAL
Interventions
NCT number NCT00027534

Go to top of page

38

Immune Responses To Antigen-Bearing Dendritic Cells in Patients With Malignancy

Status Completed
Phase Unspecified
Conditions
Start date September 2001 End date April 2011
Study type INTERVENTIONAL
Interventions
NCT number NCT00700167

Go to top of page

39

Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors

Status Completed
Phase Unspecified
Conditions
Start date March 2001 End date October 2011
Study type INTERVENTIONAL
Interventions
NCT number NCT00576537

Go to top of page

40

Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer

Status Completed
Phase Unspecified
Conditions Lung Cancer
Start date January 2001 End date August 2003
Study type INTERVENTIONAL
Interventions therapeutic autologous dendritic cells, conventional surgery, autologous tumor cell vaccine
NCT number NCT00023985

Go to top of page

41

Vaccine Therapy in Treating Patients With Liver Cancer

Status Completed
Phase Unspecified
Conditions Liver Cancer
Start date January 2001 End date October 2008
Study type INTERVENTIONAL
Interventions AFP
NCT number NCT00022334

Go to top of page

42

Therapeutic Vaccination Followed by Treatment Interruption in HIV Infected Patients

Status Completed
Phase Unspecified
Conditions HIV Infections
Start date November 2000 End date Unspecified
Study type INTERVENTIONAL
Interventions Dendritic Cells Pulsed with HIV antigens
NCT number NCT00058734

Go to top of page

43

Vaccine Biotherapy of Cancer: Autologous Tumor Cells and Dendritic Cells

Status Completed
Phase Unspecified
Conditions
Start date October 2000 End date September 2007
Study type INTERVENTIONAL
Interventions
NCT number NCT00948480

Go to top of page

44

Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Status Completed
Phase Unspecified
Conditions Lung Cancer
Start date August 2000 End date Unspecified
Study type INTERVENTIONAL
Interventions adjuvant therapy, mutant p53 peptide pulsed dendritic cell vaccine
NCT number NCT00019929

Go to top of page

45

Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma

Status Completed
Phase Unspecified
Conditions
Start date July 2000 End date April 2011
Study type INTERVENTIONAL
Interventions
NCT number NCT00012064

Go to top of page

46

Vaccine Therapy in Treating Patients With Stage III or Stage IV Kidney Cancer

Status Completed
Phase Unspecified
Conditions Kidney Cancer
Start date February 2000 End date August 2002
Study type INTERVENTIONAL
Interventions conventional surgery, therapeutic autologous dendritic cells
NCT number NCT00005816

Go to top of page

47

Vaccine Therapy in Treating Patients With Recurrent or Persistent Cervical Cancer

Status Completed
Phase Unspecified
Conditions Cervical Cancer
Start date November 1999 End date Unspecified
Study type INTERVENTIONAL
Interventions human papillomavirus 16 E7 peptide, in vitro-treated peripheral blood stem cell transplantation
NCT number NCT00003977

Go to top of page

48

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Status Completed
Phase Unspecified
Conditions Prostate Cancer
Start date November 1999 End date September 2004
Study type INTERVENTIONAL
Interventions sipuleucel-T, Placebo
NCT number NCT00005947
Results Has Results

Go to top of page

49

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer

Status Completed
Phase Unspecified
Conditions Prostate Cancer
Start date July 1999 End date January 2002
Study type INTERVENTIONAL
Interventions PSA RNA-pulsed dendritic cell vaccine
NCT number NCT00004211

Go to top of page

50

Vaccine Therapy in Treating Patients With Stage IV Melanoma

Status Completed
Phase Unspecified
Conditions Melanoma (Skin)
Start date April 1999 End date November 2002
Study type INTERVENTIONAL
Interventions tyrosinase peptide, therapeutic tumor infiltrating lymphocytes, dendritic cell-MART-1 peptide vaccine, gp100 antigen
NCT number NCT00003665

Go to top of page

51

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Status Completed
Phase Unspecified
Conditions Melanoma (Skin)
Start date April 1999 End date Unspecified
Study type INTERVENTIONAL
Interventions filgrastim, tyrosinase peptide, gp100 antigen, flu matrix peptide p58-66, recombinant MAGE-3.1 antigen, in vitro-treated peripheral blood stem cell transplantation, MART-1 antigen
NCT number NCT00003792

Go to top of page

52

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer

Status Completed
Phase Unspecified
Conditions Colorectal Cancer
Start date March 1999 End date Unspecified
Study type INTERVENTIONAL
Interventions adjuvant therapy, ras peptide cancer vaccine, aldesleukin
NCT number NCT00019591

Go to top of page

53

Immunotherapy in Treating Patients With Resected Liver Metastases From Colon Cancer

Status Completed
Phase Unspecified
Conditions Metastatic Cancer, Colorectal Cancer
Start date June 1998 End date Unspecified
Study type INTERVENTIONAL
Interventions carcinoembryonic antigen RNA-pulsed DC cancer vaccine
NCT number NCT00003433

Go to top of page

54

Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma

Status Completed
Phase Unspecified
Conditions Melanoma
Start date July 1997 End date Unspecified
Study type INTERVENTIONAL
Interventions Leukapheresis, dendritic cell-MART-1 peptide vaccine
NCT number NCT00005617

Go to top of page

55

Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal

Status Completed
Phase Unspecified
Conditions Melanoma (Skin)
Start date July 1997 End date February 2005
Study type INTERVENTIONAL
Interventions aldesleukin, gp100 antigen, tyrosinase peptide
NCT number NCT00003229

Go to top of page

56

Vaccine Therapy in Treating Patients With Advanced Kidney Cancer

Status Completed
Phase Unspecified
Conditions Kidney Cancer
Start date June 1997 End date Unspecified
Study type INTERVENTIONAL
Interventions dendritic cell vaccine therapy, conventional surgery
NCT number NCT00004880

Go to top of page

57

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Status Completed
Phase Unspecified
Conditions Melanoma (Skin)
Start date April 1997 End date Unspecified
Study type INTERVENTIONAL
Interventions aldesleukin, gp100 antigen, MART-1 antigen
NCT number NCT00019214

Go to top of page

58

Biological Therapy in Treating Patients With Metastatic Cancer

Status Completed
Phase Unspecified
Conditions Colorectal Cancer, Pancreatic Cancer, Metastatic Cancer, Ovarian Cancer, Lung Cancer, Breast Cancer, Head and Neck Cancer, Gastric Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Testicular Germ Cell Tumor, Liver Cancer
Start date February 1997 End date July 2002
Study type INTERVENTIONAL
Interventions
NCT number NCT00004604

Go to top of page

59

A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas

Status Completed
Phase Unspecified
Conditions Rhabdomyosarcoma, Ewing’s Sarcoma
Start date December 1996 End date September 2008
Study type INTERVENTIONAL
Interventions peripheral blood stem cell transplantation, indinavir sulfate, therapeutic autologous dendritic cells
NCT number NCT00001566
Results Has Results

Go to top of page

60

Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer

Status Completed
Phase Unspecified
Conditions Breast Cancer, Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Ovarian Cancer, Cervical Cancer
Start date February 1996 End date Unspecified
Study type INTERVENTIONAL
Interventions therapeutic tumor infiltrating lymphocytes, sargramostim, therapeutic autologous lymphocytes, mutant p53 peptide pulsed dendritic cell vaccine, ras peptide cancer vaccine, aldesleukin
NCT number NCT00019084

Go to top of page

61

Tumor RNA Transfected Dendritic Cell Vaccines

Status Completed
Phase Unspecified
Conditions Prostate Cancer
Start date End date September 2005
Study type INTERVENTIONAL
Interventions Tumor RNA transfected dendritic cells
NCT number NCT00108264

Go to top of page

62

Tumor Lysate Pulsed-Dendritic Cell Vaccines After High-Dose Chemotherapy for Non-Hodgkin’s Lymphoma

Status Completed
Phase Unspecified
Conditions Lymphoma, Non-Hodgkin
Start date End date Unspecified
Study type INTERVENTIONAL
Interventions tumor-pulsed dendritic cells
NCT number NCT00006434

Go to top of page

63

Safety/Immunogenicity of Immunizations of ALVAC-DC-SC vs ALVAC-SC

Status Completed
Phase Unspecified
Conditions HIV Infections
Start date End date October 2006
Study type INTERVENTIONAL
Interventions ALVAC(2)120(B,MN)GNP (vCP1452), Keyhole-Limpet Hemocyanin
NCT number NCT00026624

Go to top of page

64

Determining Responses to Two Different Vaccines in HIV and HCV Infected Individuals

Status Completed
Phase Unspecified
Conditions Hepatitis C, HIV Infections
Start date End date July 2009
Study type INTERVENTIONAL
Interventions Twinrix, Decavac
NCT number NCT00393276

Go to top of page

Not-yet-recruiting dendritic vaccine trials (4)

# Study
1

C11 AMT Positron Emission Tomography (PET) Imaging in Patients With Metastatic Invasive Breast Cancer

Status Not-yet-recruiting
Phase Unspecified
Conditions Breast Cancer
Start date August 2013 End date April 2014
Study type INTERVENTIONAL
Interventions carbon C 11 alpha-methyltryptophan, adenovirus-p53 transduced dendritic cell vaccine, 1-methyl-d-tryptophan
NCT number NCT01302821

Go to top of page

2

Dendritic Cell Vaccine For Malignant Glioma and Glioblastoma Multiforme in Adult and Pediatric Subjects

Status Not-yet-recruiting
Phase Unspecified
Conditions
Start date June 2013 End date Unspecified
Study type INTERVENTIONAL
Interventions
NCT number NCT01808820

Go to top of page

3

Combination of gp96-Ig Vaccine, Theophylline and Oxygen for the Treatment of Patients With Advanced, Relapsed or Metastatic Non-Small Cell Lung Cancer

Status Not-yet-recruiting
Phase Unspecified
Conditions
Start date April 2013 End date Unspecified
Study type INTERVENTIONAL
Interventions
NCT number NCT01799161

Go to top of page

4

Dendritic Cell Activating Scaffold in Melanoma

Status Not-yet-recruiting
Phase Unspecified
Conditions
Start date February 2013 End date Unspecified
Study type INTERVENTIONAL
Interventions
NCT number NCT01753089

Go to top of page

Follow

Get every new post delivered to your Inbox.

Join 39 other followers

%d bloggers like this: